This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CAMBRIDGE, Mass., Jan. 3, 2013 (GLOBE NEWSWIRE) --
Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the 31
st Annual J.P. Morgan Healthcare Conference in San Francisco. Marc Beer, CEO of Aegerion, is scheduled to present on Tuesday, January 8, 2013 at 2:00 pm PT (5:00 pm ET).
The presentation will be webcast live and may be accessed for up to 14 days following the conference by visiting the "
Investors" section of Aegerion's website,
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit
The Aegerion Pharmaceuticals, Inc. logo is available at
CONTACT: Aegerion Pharmaceuticals, Inc.
Michael Lawless, VP, IR